Diligence memo · auto-generated · as of July 2, 2026

Eugit Therapeutics

Eugit Therapeutics: limited disclosed financing to assess.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Eugit Therapeutics operates in Pharma, based in San Francisco, CA, USA; South San Francisco, CA, USA. Enabling Tissue Targeting of Therapies

Sub-sector tags: Biotechnology, Cell Therapy, Oncology, Synthetic Biology, Therapeutics, pharma.

Capital & rounds (filed)filed

Eugit Therapeutics has raised — in disclosed capital across 0 recorded rounds, aggregated from public filings.

Valuation (modeled)modeled

No modeled valuation — too little disclosed financing to estimate one.

Financing rhythm & timingmixed

Not enough dated financing history to read a financing rhythm.

Comparablesmixed

Capital scale ranks ahead of 16% of Pharma peers (310 compared).

Modeled value ranks above 16% of those peers.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.